article · Iranian journal of diabetes and obesity
A study conducted in Port Harcourt, Nigeria, examined the blood profiles and inflammatory markers of 70 individuals with type 2 diabetes mellitus compared to 70 matched healthy controls. Participants with diabetes showed significantly higher fasting blood glucose, glycated haemoglobin, white blood cell counts, neutrophil percentages, and levels of interleukin-1beta, which was more than three times higher than in controls. Conversely, red blood cell counts, lymphocyte percentages, and platelet indices were significantly lower in diabetic participants. Fasting blood glucose rose with longer disease duration. Glycated haemoglobin levels correlated positively with white blood cell count and certain platelet parameters, while correlating negatively with mean corpuscular volume. These findings indicate that type 2 diabetes involves distinct alterations in routine blood counts and inflammation linked directly to poor glycaemic control.
Type 2 diabetes involves persistent inflammation that can lead to severe vascular complications. By showing how standard complete blood counts and specific inflammatory markers shift with poor blood sugar control, this research highlights accessible clinical markers that can help healthcare workers identify worsening disease and stratify patient risk earlier, especially in settings with limited access to advanced diagnostic tools.
The findings point towards the potential use of routine complete blood counts and selected inflammatory markers by healthcare providers for enhanced risk stratification in diabetes monitoring. This represents an early-stage clinical insight rather than a formulated product, and the abstract indicates this approach could be particularly relevant for integration into clinical management programmes within resource-limited settings.
AI-generated from the published abstract. Always read the original work before citing.
Objective: Type 2 diabetes mellitus (T2DM) is associated with chronic hyperglycemia and systemic inflammation, which contribute to hematological alterations and vascular complications. This study evaluated hematological indices, interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) in individuals with T2DM in Port Harcourt, Nigeria, and examined their relationship with glycated hemoglobin (HbA1c). Materials and Methods: This case-control study involved 70 T2DM patients (HbA1c≥ 6.5%) and 70 age- and sex-matched healthy controls. Fasting blood glucose (FBG) was measured enzymatically, HbA1c by fluorescence immunoassay, complete blood count using an automated hematology analyzer, and cytokines by ELISA. Statistical analysis was performed using GraphPad Prism version 8.0.2, with effect sizes reported and P≤ 0.05 considered significant. Results: T2DM subjects had significantly higher FBG, HbA1c, WBC, neutrophil percentage, and IL-1β, and significantly lower RBC, lymphocyte percentage, PLT, and PCT (adjusted P< 0.05). IL-1β was more than three-fold higher in diabetics, with a very large effect size. FBG increased significantly with longer disease duration (P= 0.008). HbA1c correlated positively with FBG (P< 0.001) WBC (P= 0.044), MPV (P= 0.006), and PDW (P= 0.015), and negatively with MCV (P= 0.019) and Mixed WBC population (P= 0.001). Conclusion: This study simultaneously assessed complete blood count parameters alongside IL-1β and TNF-α in the same cohort. The findings demonstrate that T2DM in this population is characterized by clinically meaningful hematological and inflammatory alterations linked to poor glycemic control. Integrating routine complete blood count and selected inflammatory markers into diabetes monitoring may enhance early risk stratification, particularly in resource-limited settings.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.18502/ijdo.v18i3.22371
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
